Literature DB >> 11762572

Prescription of methylphenidate to children and youth, 1990-1996.

A R Miller1, C E Lalonde, K M McGrail, R W Armstrong.   

Abstract

BACKGROUND: There are concerns about the frequency and appropriateness of psychostimulant drug prescription to children. In order to identify unusual or unexpected patterns of use or prescribing, we reviewed prescription of methylphenidate (Ritalin) to children and adolescents aged 19 years or less in British Columbia between 1990 and 1996.
METHODS: We obtained information about patients, physicians and prescriptions from British Columbia's Triplicate Prescription Program database for controlled drugs. Prescription data were available for the period Jan. 1, 1990, to Dec. 31, 1996. Linkage with the BC Linked Health Dataset provided additional demographic and health information.
RESULTS: In 1990, 1715 children received at least 1 prescription for methylphenidate (1.9 per 1000 children). By 1996, the number had increased to 10,881 children (11.0 per 1000). Because some children were prescribed methylphenidate in more than 1 year, we also calculated the frequency with which the drug was prescribed to children who had never received it before. This rate increased from 1.0 per 1000 children in 1990 to 4.7 per 1000 in 1995; the rate fell in 1996 to 3.5 per 1000. The number of children receiving methylphenidate varied across health regions of the province, from 12.0 to 35.4 per 1000. Use also varied by socioeconomic status quintile: in the 2 lowest (least privileged) quintiles, 21.6 per 1000 children received methylphenidate, compared with 18.4 per 1000 in the 3 highest quintiles (relative risk 1.2, 95% confidence interval 1.1-1.2). Pediatricians and psychiatrists wrote 23% and 21% of all prescriptions respectively. General practitioners accounted for 56% of all prescriptions and 41% of initial methylphenidate prescriptions. A claim for prior specialist consultation was found in 30% of such cases. Many of the children who received more than 10 prescriptions had seen 4 or more physicians. The average daily dosage prescribed differed little among general practitioners, pediatricians and psychiatrists, unlike the mean interval between successive prescriptions: 89.9 (standard deviation [SD] 68.2), 99.8 (SD 64.1) and 75.9 (SD 70.2) days respectively. Persistence with therapy was more likely when a psychiatrist provided the initial prescription, or with involvement of more than one specialty.
INTERPRETATION: Many trends and practices in the prescription of methylphenidate to children in British Columbia are consistent with other settings and accepted standards. Some aspects warrant closer investigation, including regional and socio-economic discrepancies in the distribution of patients, the relative involvement of primary and specialist care providers, continuity of care issues and time intervals between prescriptions.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11762572      PMCID: PMC81664     

Source DB:  PubMed          Journal:  CMAJ        ISSN: 0820-3946            Impact factor:   8.262


  27 in total

Review 1.  Annotation: Principles of treatment for hyperkinetic disorder: practice approaches for the U.K.

Authors:  S Overmeyer; E Taylor
Journal:  J Child Psychol Psychiatry       Date:  1999-11       Impact factor: 8.982

2.  Moderators and mediators of treatment response for children with attention-deficit/hyperactivity disorder: the Multimodal Treatment Study of children with Attention-deficit/hyperactivity disorder.

Authors: 
Journal:  Arch Gen Psychiatry       Date:  1999-12

3.  Prevalence of methylphenidate use among adolescents in Ontario.

Authors:  F J Ivis; E M Adlaf
Journal:  Can J Public Health       Date:  1999 Sep-Oct

4.  How far is it to the nearest hospital? Calculating distances using the Statistics Canada Postal Code Conversion File.

Authors:  E Ng; R Wilkins; A Perras
Journal:  Health Rep       Date:  1993       Impact factor: 4.796

5.  Creating a population-based linked health database: a new resource for health services research.

Authors:  R Chamberlayne; B Green; M L Barer; C Hertzman; W J Lawrence; S B Sheps
Journal:  Can J Public Health       Date:  1998 Jul-Aug

Review 6.  Treatment services for children with ADHD: a national perspective.

Authors:  K Hoagwood; K J Kelleher; M Feil; D M Comer
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  2000-02       Impact factor: 8.829

Review 7.  National Institutes of Health Consensus Development Conference Statement: diagnosis and treatment of attention-deficit/hyperactivity disorder (ADHD)

Authors: 
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  2000-02       Impact factor: 8.829

Review 8.  Diagnosis and treatment of attention-deficit/hyperactivity disorder in children and adolescents. Council on Scientific Affairs, American Medical Association.

Authors:  L S Goldman; M Genel; R J Bezman; P J Slanetz
Journal:  JAMA       Date:  1998-04-08       Impact factor: 56.272

9.  Trends in the prescribing of psychotropic medications to preschoolers.

Authors:  J M Zito; D J Safer; S dosReis; J F Gardner; M Boles; F Lynch
Journal:  JAMA       Date:  2000-02-23       Impact factor: 56.272

10.  Socioeconomic status and psychiatric disorders: the causation-selection issue.

Authors:  B P Dohrenwend; I Levav; P E Shrout; S Schwartz; G Naveh; B G Link; A E Skodol; A Stueve
Journal:  Science       Date:  1992-02-21       Impact factor: 47.728

View more
  23 in total

Review 1.  Methylphenidate in the treatment of children with attention-deficit hyperactivity disorder.

Authors:  B Vitiello
Journal:  CMAJ       Date:  2001-11-27       Impact factor: 8.262

2.  Use of double-blind placebo-controlled N-of-1 trials among stimulant-treated youths in The Netherlands: a descriptive study.

Authors:  Adrianne Faber; Ron J Keizer; Paul B van den Berg; Lolkje T W de Jong-van den Berg; Hilde Tobi
Journal:  Eur J Clin Pharmacol       Date:  2006-11-18       Impact factor: 2.953

3.  Life in the last lane.

Authors:  John D Grant
Journal:  Paediatr Child Health       Date:  2002-12       Impact factor: 2.253

4.  Lifetime Prevalence of Attention-Deficit Hyperactivity Disorder in Young Adults: Examining Variations in the Socioeconomic Gradient.

Authors:  Lauren Yallop; Marni Brownell; Dan Chateau; John Walker; Michelle Warren; Dan Bailis; Michael Lebow
Journal:  Can J Psychiatry       Date:  2015-10       Impact factor: 4.356

5.  Patterns of methylphenidate use and assessment of its abuse and diversion in two French administrative areas using a proxy of deviant behaviour determined from a reimbursement database: main trends from 2005 to 2008.

Authors:  Elisabeth Frauger; Vanessa Pauly; François Natali; Vincent Pradel; Patrick Reggio; Hervé Coudert; Xavier Thirion; Joëlle Micallef
Journal:  CNS Drugs       Date:  2011-05       Impact factor: 5.749

Review 6.  Adverse effects of pharmacotherapies for attention-deficit hyperactivity disorder: epidemiology, prevention and management.

Authors:  Johnny Graham; David Coghill
Journal:  CNS Drugs       Date:  2008       Impact factor: 5.749

7.  Prevalence and patterns of methylphenidate use in French children and adolescents.

Authors:  Anne-Laure Knellwolf; Jean Deligne; Flavia Chiarotti; Guy-Robert Auleley; Serena Palmieri; Claudine Blum Boisgard; Pietro Panei; Elisabeth Autret-Leca
Journal:  Eur J Clin Pharmacol       Date:  2007-11-20       Impact factor: 2.953

Review 8.  Capacity and competence in children as research participants. Researchers have been reluctant to include children in health research on the basis of potentially naive assumptions.

Authors:  Ilina Singh
Journal:  EMBO Rep       Date:  2007-07       Impact factor: 8.807

9.  Association between ADHD drug use and injuries among children and adolescents.

Authors:  Els van den Ban; Patrick Souverein; Willemijn Meijer; Herman van Engeland; Hanna Swaab; Toine Egberts; Eibert Heerdink
Journal:  Eur Child Adolesc Psychiatry       Date:  2013-06-04       Impact factor: 4.785

10.  Co-morbidity and patterns of care in stimulant-treated children with ADHD in the Netherlands.

Authors:  Adrianne Faber; Luuk J Kalverdijk; Lolkje T W de Jong-van den Berg; Jacqueline G Hugtenburg; Ruud B Minderaa; Hilde Tobi
Journal:  Eur Child Adolesc Psychiatry       Date:  2009-11-06       Impact factor: 4.785

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.